NIAID names John Powers III permanent director

The physician-scientist has led the infectious disease institute in an acting role since June and pledges to narrow its mission away from biodefense.

By Ruth Kaplan, Health systems correspondent
. 2-minute read.
Illustration: NIAID headquarters Bethesda
Illustration: Clinical Observer

The National Institute of Allergy and Infectious Diseases said Monday that John Powers III, its acting director, will take the job permanently, STAT reported. Powers has led the institute in an acting capacity since June. The institute has been without a permanent director since March 2025, when the Trump administration forced out Jeanne Marrazzo. A physician-scientist, Powers has worked at NIAID since 1999 in roles focused on clinical research. NIAID drew renewed focus under the second Trump administration, driven by the president's anger at former director Anthony Fauci and unfounded claims that a Chinese institute's research, funded by NIAID, helped create SARS-CoV-2. Following Marrazzo's removal, Jeffery Taubenberger became acting director, then abruptly left; other senior NIAID officials were moved to different institutes or told to resign.

On a call with journalists Monday, Powers said the agency would refocus on its core remit of sharing public information about infectious, allergic, and autoimmune diseases, stepping back from biodefense as a central agency goal, the Washington Examiner reported. "It actually says in our congressional remit for the formulation of this institute that dissemination of scientific information is in our remit," Powers said. "So that's our job: actually put the information out and then to help clinicians and the patients to understand where a particular intervention might be beneficial or not."

A Temple University medical school graduate, Powers has practiced as an infectious disease physician at NIAID since 1999. Before coming to NIH, Powers led antimicrobial drug development at the Food and Drug Administration as its lead medical officer. NIH Director Jay Bhattacharya said in a statement that Powers "has spent more than three decades caring for patients, teaching and mentoring the next generation of investigators, and playing an integral role in research that improves lives." Bhattacharya said Powers "will bring a focus on rigor, transparency, and research outcomes to leading the institute into the future."

Powers said the institute would use its nearly $6.6 billion annual budget to deepen understanding of how the human immune system interacts with diseases and treatments. "We are continuing to do work on individual microbes, but really a lot of the reasoning behind why people aren't doing better on current therapy has a lot to do with the host immunologic response," he said.

Asked about gain-of-function research, Powers said his priority is "to work on diseases that are actually harming people today" rather than anticipating the next pathogen. He did not directly answer questions about whether vaccines cause autism, saying, "My reading of the literature is not what's relevant," and describing such questions as "child development issues more than anything else."

Sources: STAT, Washington Examiner

Ruth KaplanHealth systems correspondent

Ruth Kaplan covers hospitals, health systems and the business of care for Clinical Observer. She writes from published reporting, filings and official statements.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.